A Phase I Safety and Pharmacokinetic Study of Everolimus, an Oral mTOR Inhibitor, in Subjects With Impaired Hepatic Function

Peveling-Oberhag J.¹ , Zeuzem S.¹ , Yong W.P.² , Kunz T.³ , Paquet T.⁴ , Bouillaud E.⁴ , Urva S.³ , Anak O.⁴ , Sellami D.³ , Kobalava Z. ⁵

EUROPEAN JOURNAL OF CANCER

ELSEVIER SCI LTD

Английский

Опубликовано

10.1016/S0959-8049(11)71871-8

47

2011

• ¹ Klin JW Goethe Univ, Dept Med, Frankfurt 117548, Germany
• ² Natl Univ Singapore, Inst Canc, Singapore, Singapore
• ³ Novartis Pharmaceut, NIA, Florham Pk, NJ USA
• ⁴ Novartis Pharma AG, NIA, Basel, Switzerland
• ⁵ Peoples Friendship Univ Russia, Ctr Appl Clin Pharmacol, Moscow, Russia